An agreement was reached with Longmont-based Chemizon and the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to spin out a new biotech company designed to commercialize KRIBB’s intellectual property assets with an emphasis on technologies targeting the discovery of drugs that address unmet medical needs. The deal is led by Chemizon-Oakwood Bioventures private equity [...]

• 319http://clsdf.com/2008/02/chemizon-oakwood-bioventures-to-fund-newco/Chemizon-Oakwood+Bioventures+to+Fund+NewCo2008-02-15+15%3A36%3A00admin

News continues to pour out of Pharmion (NASDAQ: PHRM) of late and believe it or not today’s tidbit is not related to the Celgene (NASDAQ: CELG) acquisition, rather it is focused on the MGCD0103 product for the treatment of acute Myelogenous Leukemia with development and commercialization partner MethylGene (TSX: MYG). This week proved very encouraging [...]

• 318http://clsdf.com/2008/02/pharmion-market-exclusisivity/Pharmion%3A+Market+Exclusisivity2008-02-15+14%3A49%3A00admin